These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 38170407

  • 1. Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer.
    Eckhoff AM, Kanu E, Fletcher A, Bao M, Aushev VN, Spickard E, Nussbaum DP, Allen PJ.
    Ann Surg Oncol; 2024 Mar; 31(3):1444-1446. PubMed ID: 38170407
    [Abstract] [Full Text] [Related]

  • 2. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma.
    Botta GP, Abdelrahim M, Drengler RL, Aushev VN, Esmail A, Laliotis G, Brewer CM, George GV, Abbate SM, Chandana SR, Tejani MA, Malla M, Bansal D, Rivero-Hinojosa S, Spickard E, McCormick N, Cecchini M, Lacy J, Fei N, Kasi PM, Kasi A, Dayyani F, Hanna DL, Sharma S, Malhotra M, Aleshin A, Liu MC, Jurdi A.
    Oncologist; 2024 Oct 03; 29(10):859-869. PubMed ID: 39022993
    [Abstract] [Full Text] [Related]

  • 3. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
    Tie J, Wang Y, Cohen J, Li L, Hong W, Christie M, Wong HL, Kosmider S, Wong R, Thomson B, Choi J, Fox A, Field K, Burge M, Shannon J, Kotasek D, Tebbutt NC, Karapetis C, Underhill C, Haydon A, Schaeffer J, Ptak J, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P.
    PLoS Med; 2021 May 03; 18(5):e1003620. PubMed ID: 33939694
    [Abstract] [Full Text] [Related]

  • 4. Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer.
    Groot VP, Mosier S, Javed AA, Teinor JA, Gemenetzis G, Ding D, Haley LM, Yu J, Burkhart RA, Hasanain A, Debeljak M, Kamiyama H, Narang A, Laheru DA, Zheng L, Lin MT, Gocke CD, Fishman EK, Hruban RH, Goggins MG, Molenaar IQ, Cameron JL, Weiss MJ, Velculescu VE, He J, Wolfgang CL, Eshleman JR.
    Clin Cancer Res; 2019 Aug 15; 25(16):4973-4984. PubMed ID: 31142500
    [Abstract] [Full Text] [Related]

  • 5. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.
    Lee B, Lipton L, Cohen J, Tie J, Javed AA, Li L, Goldstein D, Burge M, Cooray P, Nagrial A, Tebbutt NC, Thomson B, Nikfarjam M, Harris M, Haydon A, Lawrence B, Tai DWM, Simons K, Lennon AM, Wolfgang CL, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P.
    Ann Oncol; 2019 Sep 01; 30(9):1472-1478. PubMed ID: 31250894
    [Abstract] [Full Text] [Related]

  • 6. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Chidharla A, Rapoport E, Agarwal K, Madala S, Linares B, Sun W, Chakrabarti S, Kasi A.
    Int J Mol Sci; 2023 Jun 16; 24(12):. PubMed ID: 37373376
    [Abstract] [Full Text] [Related]

  • 7. Association of preoperative and postoperative circulating tumour DNA (ctDNA) with PIK3CA gene mutation with risk of recurrence in patients with non-metastatic breast cancer.
    Hassan F, Wang JH, O'Leary DP, Corrigan M, Redmond HP.
    Surg Oncol; 2024 Jun 16; 54():102060. PubMed ID: 38603927
    [Abstract] [Full Text] [Related]

  • 8. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
    Tarazona N, Gimeno-Valiente F, Gambardella V, Zuñiga S, Rentero-Garrido P, Huerta M, Roselló S, Martinez-Ciarpaglini C, Carbonell-Asins JA, Carrasco F, Ferrer-Martínez A, Bruixola G, Fleitas T, Martín J, Tébar-Martínez R, Moro D, Castillo J, Espí A, Roda D, Cervantes A.
    Ann Oncol; 2019 Nov 01; 30(11):1804-1812. PubMed ID: 31562764
    [Abstract] [Full Text] [Related]

  • 9. Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment.
    Parikh AR, Chee BH, Tsai J, Rich TA, Price KS, Patel SA, Zhang L, Ibrahim F, Esquivel M, Van Seventer EE, Jarnagin JX, Raymond VM, Corvera CU, Hirose K, Nakakura EK, Corcoran RB, Van Loon K, Atreya CE.
    Clin Cancer Res; 2024 Jul 15; 30(14):2964-2973. PubMed ID: 38695832
    [Abstract] [Full Text] [Related]

  • 10. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
    Radovich M, Jiang G, Hancock BA, Chitambar C, Nanda R, Falkson C, Lynce FC, Gallagher C, Isaacs C, Blaya M, Paplomata E, Walling R, Daily K, Mahtani R, Thompson MA, Graham R, Cooper ME, Pavlick DC, Albacker LA, Gregg J, Solzak JP, Chen YH, Bales CL, Cantor E, Shen F, Storniolo AMV, Badve S, Ballinger TJ, Chang CL, Zhong Y, Savran C, Miller KD, Schneider BP.
    JAMA Oncol; 2020 Sep 01; 6(9):1410-1415. PubMed ID: 32644110
    [Abstract] [Full Text] [Related]

  • 11. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer.
    Li N, Wang BX, Li J, Shao Y, Li MT, Li JJ, Kuang PP, Liu Z, Sun TY, Wu HQ, Ou W, Wang SY.
    Cancer; 2022 Feb 15; 128(4):708-718. PubMed ID: 35076939
    [Abstract] [Full Text] [Related]

  • 12. Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer.
    Tan AC, Lai GGY, Saw SPL, Chua KLM, Takano A, Ong BH, Koh TPT, Jain A, Tan WL, Ng QS, Kanesvaran R, Rajasekaran T, Kalashnikova E, Renner D, Sudhaman S, Malhotra M, Sethi H, Liu MC, Aleshin A, Lim WT, Tan EH, Skanderup AJ, Ang MK, Tan DSW.
    Cancer; 2024 May 15; 130(10):1758-1765. PubMed ID: 38422026
    [Abstract] [Full Text] [Related]

  • 13. Tissue-Free Liquid Biopsies Combining Genomic and Methylation Signals for Minimal Residual Disease Detection in Patients with Early Colorectal Cancer from the UK TRACC Part B Study.
    Slater S, Bryant A, Aresu M, Begum R, Chen HC, Peckitt C, Lazaro-Alcausi R, Carter P, Anandappa G, Khakoo S, Melcher L, Potter V, Marti FM, Huang J, Branagan G, George N, Abulafi M, Duff S, Raja A, Gupta A, West N, Bucheit L, Rich T, Chau I, Cunningham D, Starling N, TRACC Part B trial investigators.
    Clin Cancer Res; 2024 Aug 15; 30(16):3459-3469. PubMed ID: 38864835
    [Abstract] [Full Text] [Related]

  • 14. Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical resection.
    Hata T, Mizuma M, Motoi F, Ohtsuka H, Nakagawa K, Morikawa T, Unno M.
    J Hepatobiliary Pancreat Sci; 2023 Jun 15; 30(6):815-824. PubMed ID: 36408698
    [Abstract] [Full Text] [Related]

  • 15. Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments.
    Oh Y, Yoon SM, Lee J, Park JH, Lee S, Hong T, Chung LI, Sudhaman S, Riddell T, Palsuledesai CC, Krainock M, Liu MC, Chae YK.
    Thorac Cancer; 2024 May 15; 15(13):1095-1102. PubMed ID: 38558374
    [Abstract] [Full Text] [Related]

  • 16. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
    Wang DS, Yang H, Liu XY, Chen ZG, Wang Y, Fong WP, Hu MT, Zheng YC, Zheng Y, Li BK, Yuan YF, Chen G, Pan ZZ, Song L, Li YH, Xu RH.
    Theranostics; 2021 May 15; 11(14):7018-7028. PubMed ID: 34093868
    [Abstract] [Full Text] [Related]

  • 17. Parallel Analysis of Pre- and Postoperative Circulating Tumor DNA and Matched Tumor Tissues in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Cohort Study.
    Lee JS, Han Y, Yun WG, Kwon W, Kim H, Jeong H, Seo MS, Park Y, Cho SI, Kim H, Kim JY, Seong MW, Jang JY, Park SS.
    Clin Chem; 2022 Dec 06; 68(12):1509-1518. PubMed ID: 36177751
    [Abstract] [Full Text] [Related]

  • 18. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer.
    Yang J, Gong Y, Lam VK, Shi Y, Guan Y, Zhang Y, Ji L, Chen Y, Zhao Y, Qian F, Chen J, Li P, Zhang F, Wang J, Zhang X, Yang L, Kopetz S, Futreal PA, Zhang J, Yi X, Xia X, Yu P.
    Cell Death Dis; 2020 May 11; 11(5):346. PubMed ID: 32393783
    [Abstract] [Full Text] [Related]

  • 19. Association of circulating tumor DNA with patient prognosis in surgically resected renal cell carcinoma.
    Correa AF, Kalashnikova E, Wu HT, Winters RM, Balcioglu M, Sudhaman S, Connolly DC, Gong Y, Uzzo RG, Sethi H, ElNaggar AC, Aleshin A, Liu MC, Abbosh PH.
    Oncologist; 2024 Oct 03; 29(10):887-893. PubMed ID: 39013784
    [Abstract] [Full Text] [Related]

  • 20. Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
    Lipsyc-Sharf M, de Bruin EC, Santos K, McEwen R, Stetson D, Patel A, Kirkner GJ, Hughes ME, Tolaney SM, Partridge AH, Krop IE, Knape C, Feger U, Marsico G, Howarth K, Winer EP, Lin NU, Parsons HA.
    J Clin Oncol; 2022 Aug 01; 40(22):2408-2419. PubMed ID: 35658506
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.